Search

  • HOME
  • Search
Letter to the Editor
1631
Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura
Clin Mol Hepatol. 2021;27(4):616-619.   Published online September 13, 2021
Original Article
1627
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
Hideyuki Tamai, Jumpei Okamura
Clin Mol Hepatol. 2021;27(4):564-574.   Published online August 2, 2021
Original Article
1607
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong
Clin Mol Hepatol. 2021;27(3):499-509.   Published online February 26, 2021
Review
1621
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Clin Mol Hepatol. 2021;27(3):402-412.   Published online June 23, 2021
Original Article
1570
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, Ming-Lung Yu
Clin Mol Hepatol. 2021;27(2):313-328.   Published online December 14, 2020
1581
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Clin Mol Hepatol. 2021;27(2):295-304.   Published online December 3, 2020
Review
1580
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clin Mol Hepatol. 2021;27(2):236-245.   Published online December 3, 2020
Original Article
1564
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon
Clin Mol Hepatol. 2021;27(1):157-174.   Published online November 26, 2020
1567
Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park
Clin Mol Hepatol. 2021;27(1):144-156.   Published online December 7, 2020
Editorial
Old hepatitis B virus never dies: It just hides itself within the host genome
Jeong-Hoon Lee
Clin Mol Hepatol. 2021;27(1):107-109.   Published online December 23, 2020
1590
Metabolic disease as a risk of hepatocellular carcinoma
Naoshi Nishida
Clin Mol Hepatol. 2021;27(1):87-90.   Published online December 3, 2020
Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
Yuchen Liu, Xiaohui Wang, Yingzi Yang
Clin Mol Hepatol. 2020;26(4):742-750.   Published online September 28, 2020
Letter to the Editor
Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
Jeong Su Park, Soo Han Bae
Clin Mol Hepatol. 2020;26(4):577-578.   Published online September 17, 2020
Original Article
Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway
Seulki Lee, Eun Ji Choi, Eun Ju Cho, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol. 2020;26(4):529-539.   Published online August 24, 2020
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol. 2020;26(4):516-528.   Published online September 11, 2020
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clin Mol Hepatol. 2020;26(4):506-515.   Published online July 10, 2020
Original Article
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park
Clin Mol Hepatol. 2020;26(3):364-375.   Published online May 29, 2020
Original Article
Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma
Rahul Kumar, Boon-Bee George Goh, Jia-Wen Kam, Pik-Eu Chang, Chee-Kiat Tan
Clin Mol Hepatol. 2020;26(2):196-208.   Published online January 9, 2020
Review
1495
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Clin Mol Hepatol. 2020;26(2):155-162.   Published online January 15, 2020
Original Article
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti
Clin Mol Hepatol. 2020;26(1):45-53.   Published online September 30, 2019
1464
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim
Clin Mol Hepatol. 2020;26(1):24-32.   Published online May 20, 2019
Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
Kei Moriya, Tadashi Namisaki, Shinya Sato, Masanori Furukawa, Akitoshi Douhara, Hideto Kawaratani, Kosuke Kaji, Naotaka Shimozato, Yasuhiko Sawada, Soichiro Saikawa, Hiroaki Takaya, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji
Clin Mol Hepatol. 2019;25(4):381-389.   Published online August 13, 2019
1 | 2 | 3 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 470
TOTAL : 660141
Close layer